• Profile
Close

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: The C-SCAPE study

Journal of Viral Hepatitis Nov 23, 2017

Brown A, et al. - Authors performed the phase 2 C-SCAPE study to evaluate elbasvir/grazoprevir (EBR/GZR), with or without ribavirin (RBV), in participants with hepatitis C virus (HCV) genotype 2, 4, 5 or 6 infection. As per findings, the inclusion of participants with genotype 4 or 6 infection in the EBR/GZR phase 3 studies was supported. For participants with genotype 2 or 5 infection, EBR/GZR±RBV seemed unsatisfactory.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay